{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T17:24:07Z","timestamp":1768325047999,"version":"3.49.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The COVID-19 pandemic has had significant impacts on how mental health services are delivered to patients throughout Canada. The reduction of in-person healthcare services have created unique challenges for individuals with psychotic disorders that require regular clinic visits to administer and monitor long-acting injectable antipsychotic medications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>To better understand how LAI usage was impacted, national and provincial patient-level longitudinal prescribing data from Canadian retail pharmacies were used to examine LAI prescribing practices during the pandemic. Prescribing data on new starts of medication, discontinuations of medications, switches between medications, antipsychotic name, concomitant medications, payer plan, gender and age were collected from January 2019 to December 2020 for individuals \u226518-years of age, and examined by month, as well as by distinct pandemic related epochs characterized by varying degrees of public awareness, incidence of COVID-19 infections and public health restrictions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>National, and provincial level data revealed that rates of LAI prescribing including new starts, discontinuations and switches between LAI products remained highly stable (i.e., no statistically significant differences) throughout the study period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Equal numbers of LAI new starts and discontinuations prior to and during the pandemic suggests prescribing of LAI antipsychotics, for those already in care, continued unchanged throughout the pandemic. The observed consistency of LAI prescribing contrasts with other areas of healthcare, such as cardiovascular and diabetes care, which experienced decreases in medication prescribing during the COVID-19 pandemic.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-021-03646-9","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T18:02:45Z","timestamp":1640023365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study"],"prefix":"10.1186","volume":"21","author":[{"given":"Kyle A.","family":"McKee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candice E.","family":"Crocker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip G.","family":"Tibbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"issue":"10227","key":"3646_CR1","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/S0140-6736(20)30460-8","volume":"395","author":"SK Brooks","year":"2020","unstructured":"Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet Lond Engl. 2020;395(10227):912\u201320.","journal-title":"Lancet Lond Engl"},{"key":"3646_CR2","doi-asserted-by":"publisher","first-page":"113111","DOI":"10.1016\/j.psychres.2020.113111","volume":"290","author":"CK Kaparounaki","year":"2020","unstructured":"Kaparounaki CK, Patsali ME, Mousa D-PV, Papadopoulou EVK, Papadopoulou KKK, Fountoulakis KN. University students\u2019 mental health amidst the COVID-19 quarantine in Greece. Psychiatry Res. 2020;290:113111.","journal-title":"Psychiatry Res"},{"issue":"4","key":"3646_CR3","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1093\/schbul\/sbaa051","volume":"46","author":"N Kozloff","year":"2020","unstructured":"Kozloff N, Mulsant BH, Stergiopoulos V, Voineskos AN. The COVID-19 global pandemic: implications for people with schizophrenia and related disorders. Schizophr Bull. 2020;46(4):752\u20137.","journal-title":"Schizophr Bull"},{"key":"3646_CR4","doi-asserted-by":"crossref","unstructured":"Hanafi S, Dufour M, Dor\u00e9-Gauthier V, Prasad MR, Charbonneau M, Beck G. COVID-19 and Canadian Psychiatry: La COVID-19 et la psychiatrie au Canada. Can J Psychiatry. 2020;66:832\u201341.","DOI":"10.1177\/07067437211007283"},{"key":"3646_CR5","volume-title":"Position Statement on Long Acting Injectables","year":"2020","unstructured":"North Carolina Psychiatric Association, editor. Position Statement on Long Acting Injectables. 2020. Available from: https:\/\/www.psychiatry.org\/File%20Library\/Psychiatrists\/APA-Guidance-Long-Acting-Injectables-COVID-19.pdf."},{"key":"3646_CR6","doi-asserted-by":"crossref","unstructured":"Nystazaki M, Karanikola M. Long acting injectable antipsychotics: uninterrupted use during the COVID-19 pandemic. J Psychiatr Ment Hlt. 2021 [Advance online publication].","DOI":"10.1111\/jpm.12750"},{"issue":"3","key":"3646_CR7","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1192\/bjp.2020.92","volume":"217","author":"JJ Luykx","year":"2020","unstructured":"Luykx JJ, van VSMP, Risselada A, Naarding P, Tijdink JK, Vinkers CH. Safe and informed prescribing of psychotropic medication during the COVID-19 pandemic. Br J Psychiatry. 2020;217(3):471\u20134.","journal-title":"Br J Psychiatry"},{"key":"3646_CR8","doi-asserted-by":"crossref","unstructured":"MacLaurin SA, Mulligan C, Alphen MUV, Freudenreich O. Optimal long-acting injectable antipsychotic management during COVID-19. J Clin Psychiatry. 2021;82(1):0\u20130.","DOI":"10.4088\/JCP.20l13730"},{"issue":"2","key":"3646_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.12788\/cp.0087","volume":"20","author":"K Schnitzer","year":"2021","unstructured":"Schnitzer K, MacLaurin S, Freudenreich O. Long-acting injectable antipsychotics during COVID-19. Curr Psychiatr Ther. 2021;20(2):8\u201313.","journal-title":"Curr Psychiatr Ther"},{"key":"3646_CR10","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.schres.2020.05.001","volume":"222","author":"JM Gannon","year":"2020","unstructured":"Gannon JM, Conlogue J, Sherwood R, Nichols J, Ballough JR, Fredrick NM, et al. Long acting injectable antipsychotic medications: ensuring care continuity during the COVID-19 pandemic restrictions. Schizophr Res. 2020;222:532\u20133.","journal-title":"Schizophr Res"},{"key":"3646_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.schres.2020.04.030","volume":"220","author":"P Ifteni","year":"2020","unstructured":"Ifteni P, Dima L, Teodorescu A. Long-acting injectable antipsychotics treatment during COVID-19 pandemic \u2013 a new challenge. Schizophr Res. 2020;220:265\u20136.","journal-title":"Schizophr Res"},{"issue":"2","key":"3646_CR12","first-page":"223","volume":"271","author":"J Henssler","year":"2021","unstructured":"Henssler J, Stock F, van BJ, Walter H, Heinz A, Brandt L. Mental health effects of infection containment strategies: quarantine and isolation\u2014a systematic review and meta-analysis. Eur Arch Psy Clin N. 2021;271(2):223\u201334.","journal-title":"Eur Arch Psy Clin N"},{"issue":"1","key":"3646_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3390\/healthcare9010101","volume":"9","author":"M Cavicchioli","year":"2021","unstructured":"Cavicchioli M, Ferrucci R, Guidetti M, Canevini MP, Pravettoni G, Galli F. What will be the impact of the COVID-19 quarantine on psychological distress? Considerations based on a systematic review of pandemic outbreaks. Healthc. 2021;9(1):101.","journal-title":"Healthc."},{"key":"3646_CR14","doi-asserted-by":"publisher","first-page":"113999","DOI":"10.1016\/j.psychres.2021.113999","volume":"302","author":"N Nejati","year":"2021","unstructured":"Nejati N, Crocker C, Kolajova M, Morrison J, Simon P, Sridharan S, et al. Examination of the impact of COVID-19 public health quarantine measures on acute mental health care services: a retrospective observational study. Psychiatry Res. 2021;302:113999.","journal-title":"Psychiatry Res"},{"key":"3646_CR15","volume-title":"Real world longitudinal prescription (LRx) data","author":"IQVIA","year":"2019","unstructured":"IQVIA. Real world longitudinal prescription (LRx) data. 2019. Available from: https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/belgium\/lrx-product-factsheet-iqvia.pdf"},{"key":"3646_CR16","volume-title":"Epidemiological summary of COVID-19 cases in Canada","author":"Government of Canada","year":"2021","unstructured":"Government of Canada. Epidemiological summary of COVID-19 cases in Canada. 2021 [cited 2021 Sep 19]. Available from: https:\/\/health-infobase.canada.ca\/covid-19\/epidemiological-summary-covid-19-cases.html#a4"},{"issue":"2","key":"3646_CR17","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/JCP.0000000000000672","volume":"37","author":"H Rittmannsberger","year":"2017","unstructured":"Rittmannsberger H, Rosenleitner J, Malsiner-Walli G, Werl R, Rittmannsberger B, Yazdi K. Treatment duration with long-acting injectable antipsychotics after in-hospital initiation. J Clin Psychopharmacol. 2017;37(2):250\u20134.","journal-title":"J Clin Psychopharmacol"},{"issue":"11","key":"3646_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13696998.2019.1615927","volume":"22","author":"X Song","year":"2019","unstructured":"Song X, Khoury ACE, Brouillette M, Smith D, Joshi K. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia. J Med Econ. 2019;22(11):1.","journal-title":"J Med Econ"},{"issue":"5","key":"3646_CR19","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/acps.12722","volume":"135","author":"H Verdoux","year":"2017","unstructured":"Verdoux H, Pambrun E, Tournier M, Bezin J, Pariente A. Risk of discontinuation of antipsychotic long-acting injections vs. oral antipsychotics in real-life prescribing practice: a community-based study. Acta Psychiatr Scand. 2017;135(5):429\u201338.","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"3646_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/JCP.0000000000001148","volume":"40","author":"D Janzen","year":"2019","unstructured":"Janzen D, Bolton J, Kuo I, fan, Leong C, Alessi-Severini S. Trends in the use of long-acting injectable antipsychotics in the province of Manitoba, Canada. J Clin Psychopharmacol. 2019;40(1):6\u201313.","journal-title":"J Clin Psychopharmacol"},{"key":"3646_CR21","unstructured":"Burke D. COVID-19 fears fuel rise in heart attacks in Nova Scotia. CBC. 2021; [cited 2021 Jun 16]. Available from: https:\/\/www.cbc.ca\/news\/canada\/nova-scotia\/heart-attacks-stroke-prevention-health-care-research-1.5977964."},{"key":"3646_CR22","volume-title":"Private Drug Plan Database [database]","author":"IQVIA","year":"2021","unstructured":"IQVIA. Private Drug Plan Database [database]: Unpublished data; 2021."},{"issue":"1","key":"3646_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.healthpol.2011.08.015","volume":"104","author":"JR Daw","year":"2012","unstructured":"Daw JR, Morgan SG. Stitching the gaps in the Canadian public drug coverage patchwork? A review of provincial pharmacare policy changes from 2000 to 2010. Health Policy. 2012;104(1):19\u201326.","journal-title":"Health Policy"},{"issue":"1","key":"3646_CR24","doi-asserted-by":"publisher","first-page":"E167","DOI":"10.9778\/cmajo.20180198","volume":"7","author":"MR Law","year":"2019","unstructured":"Law MR, Cheng L, Worthington H, Majumdar SR, McGrail KM, Chan F, et al. Impact of a household-level deductible on prescription drug use among lower-income adults: a quasi-experimental study. Cmaj Open. 2019;7(1):E167\u201373.","journal-title":"Cmaj Open"},{"issue":"5","key":"3646_CR25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3111\/13696998.2014.1001514","volume":"18","author":"O Baser","year":"2015","unstructured":"Baser O, Xie L, Pesa J, Durkin M. Healthcare utilization and costs of veterans health administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics. J Med Econ. 2015;18(5):357\u201365.","journal-title":"J Med Econ"},{"key":"3646_CR26","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.1016\/j.jval.2021.04.648","volume":"24","author":"J Pesa","year":"2021","unstructured":"Pesa J, Liberman JN, Petrillo M, Ruetsch C. PMH26 early impact of COVID-19 pandemic on antipsychotic medication use among patients with schizophrenia. Value Health. 2021;24:S132.","journal-title":"Value Health"},{"issue":"2","key":"3646_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","volume":"20","author":"LN Yatham","year":"2018","unstructured":"Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian network for mood and anxiety treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97\u2013170.","journal-title":"Bipolar Disord"},{"key":"3646_CR28","doi-asserted-by":"crossref","unstructured":"Davis LL, Ryan W, Adinoff B, Petty F. Comprehensive review of the psychiatric uses of valproate. J Clin Psychopharmacol. 2000;20(1) Available from: https:\/\/journals.lww.com\/psychopharmacology\/Fulltext\/2000\/02001\/Comprehensive_Review_of_the_Psychiatric_Uses_of.1.aspx.","DOI":"10.1097\/00004714-200002001-00001"},{"issue":"5","key":"3646_CR29","first-page":"301","volume":"4","author":"H Belli","year":"2012","unstructured":"Belli H, Ural C, Akbudak M. Borderline personality disorder: bipolarity, mood stabilizers and atypical antipsychotics in treatment. J Clin Med Res. 2012;4(5):301\u20138.","journal-title":"J Clin Med Res"},{"key":"3646_CR30","volume-title":"Atypical Injectable Antipsychotics for Schizophrenia or Bipolar Disorder: A Review of Clinical Effectiveness and Cost-Effectiveness","author":"T Narain","year":"2019","unstructured":"Narain T, Ford C. Atypical Injectable Antipsychotics for Schizophrenia or Bipolar Disorder: A Review of Clinical Effectiveness and Cost-Effectiveness. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019. (CADTH Rapid Response Reports). Available from: http:\/\/europepmc.org\/books\/NBK541213"},{"issue":"1","key":"3646_CR31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1192\/bjp.bp.112.122499","volume":"205","author":"T Gerhard","year":"2014","unstructured":"Gerhard T, Huybrechts K, Olfson M, Schneeweiss S, Bobo WV, Doraiswamy PM, et al. Comparative mortality risks of antipsychotic medications in community-dwelling older adults. Brit J Psychiat. 2014;205(1):44\u201351.","journal-title":"Brit J Psychiat"},{"issue":"12","key":"3646_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11920-017-0847-x","volume":"19","author":"B Pignon","year":"2017","unstructured":"Pignon B, du MCT, Carton L, Pelissolo A. The place of antipsychotics in the therapy of anxiety disorders and obsessive-compulsive disorders. Curr Psychiat Rep. 2017;19(12):103.","journal-title":"Curr Psychiat Rep"},{"key":"3646_CR33","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fneur.2012.00073","volume":"3","author":"J Cerejeira","year":"2012","unstructured":"Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol. 2012;3:73.","journal-title":"Front Neurol"},{"key":"3646_CR34","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.schres.2017.12.010","volume":"197","author":"H Taipale","year":"2018","unstructured":"Taipale H, Mittendorfer-Rutz E, Alexanderson K, Majak M, Meht\u00e4l\u00e4 J, Hoti F, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res. 2018;197:274\u201380.","journal-title":"Schizophr Res"},{"issue":"1","key":"3646_CR35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40261-020-00990-8","volume":"41","author":"J Mahlich","year":"2021","unstructured":"Mahlich J, Olbrich K, Wilk A, Wimmer A, Wolff-Menzler C. Time to treatment discontinuation in German patients with schizophrenia: long-acting Injectables versus Oral antipsychotics. Clin Drug Invest. 2021;41(1):99\u2013113.","journal-title":"Clin Drug Invest"},{"issue":"10","key":"3646_CR36","doi-asserted-by":"publisher","first-page":"e0139403","DOI":"10.1371\/journal.pone.0139403","volume":"10","author":"AM Gaviria","year":"2015","unstructured":"Gaviria AM, Franco JG, Aguado V, Rico G, Labad J, de PJ, et al. A non-interventional naturalistic study of the prescription patterns of antipsychotics in patients with schizophrenia from the Spanish Province of Tarragona. PLoS One. 2015;10(10):e0139403.","journal-title":"PLoS One"},{"key":"3646_CR37","doi-asserted-by":"publisher","first-page":"204512532095711","DOI":"10.1177\/2045125320957118","volume":"10","author":"E Stip","year":"2020","unstructured":"Stip E, Javaid S, Bayard-Diotte J, Aziz KA, Arnone D. Use of long acting antipsychotics and relationship to newly diagnosed bipolar disorder: a pragmatic longitudinal study based on a Canadian health registry. Ther Adv Psychopharmacol. 2020;10:2045125320957118.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"11","key":"3646_CR38","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/2045125318782694","volume":"8","author":"E Stip","year":"2018","unstructured":"Stip E, Lachaine J. Real-world effectiveness of long-acting antipsychotic treatments in a nationwide cohort of 3957 patients with schizophrenia, schizoaffective disorder and other diagnoses in Quebec. Ther Adv Psychopharmacol. 2018;8(11):287\u2013301.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"4","key":"3646_CR39","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1001\/jamapsychiatry.2020.4442","volume":"78","author":"K Nemani","year":"2021","unstructured":"Nemani K, Li C, Olfson M, Blessing EM, Razavian N, Chen J, et al. Association of Psychiatric Disorders with Mortality among Patients with COVID-19. JAMA Psychiat. 2021;78(4):380\u20136.","journal-title":"JAMA Psychiat"},{"issue":"12","key":"3646_CR40","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S2215-0366(20)30421-1","volume":"7","author":"SW Lee","year":"2020","unstructured":"Lee SW, Yang JM, Moon SY, Yoo IK, Ha EK, Kim SY, et al. Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: a nationwide cohort study. Lancet Psychiatry. 2020;7(12):1025\u201331.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"3646_CR41","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/wps.20806","volume":"20","author":"Q Wang","year":"2021","unstructured":"Wang Q, Xu R, Volkow ND. Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States. World Psychiatry. 2021;20(1):124\u201330.","journal-title":"World Psychiatry"},{"key":"3646_CR42","doi-asserted-by":"crossref","unstructured":"Shinn AK, Viron M. Perspectives on the COVID-19 pandemic and individuals with serious mental illness. J Clin Psychiatry. 2020;81(3):0\u20130.","DOI":"10.4088\/JCP.20com13412"},{"issue":"18","key":"3646_CR43","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1007\/s40265-017-0830-1","volume":"77","author":"J Dyall","year":"2017","unstructured":"Dyall J, Gross R, Kindrachuk J, Johnson RF, Olinger GG, Hensley LE, et al. Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies. Drugs. 2017;77(18):1935\u201366.","journal-title":"Drugs."},{"key":"3646_CR44","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.schres.2021.02.002","volume":"229","author":"M Canal-Rivero","year":"2021","unstructured":"Canal-Rivero M, Barrag\u00e1n RC, Garc\u00eda AR, Torres NG, Crespo-Facorro B, Ruiz-Veguilla M, et al. Lower risk of SARS-CoV2 infection in individuals with severe mental disorders on antipsychotic treatment: a retrospective epidemiological study in a representative Spanish population. Schizophr Res. 2021;229:53\u20134.","journal-title":"Schizophr Res"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-021-03646-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-021-03646-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-021-03646-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T18:10:25Z","timestamp":1640023825000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-021-03646-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3646"],"URL":"https:\/\/doi.org\/10.1186\/s12888-021-03646-9","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"21 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were carried out in accordance with relevant guidelines and regulations. Ethical approval for this retrospective study of administrative data, including a waiver of informed consent was given by the Nova Scotia Health Authority Research Ethics Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Author P.G.T has received honoraria for speaking and has sat on advisory boards for Janssen Inc., Abbvie, and Otsuka Lundbeck alliance, outside the submitted work. The remaining authors have no competing financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"633"}}